Intended for healthcare professionals


In brief

BMJ 2006; 332 doi: (Published 11 May 2006) Cite this as: BMJ 2006;332:1110

Inhaled insulin fails to convince watchdog: The German equivalent of England and Wales's National Institute for Health and Clinical Excellence has pointed out the lack of evidence showing that inhaled insulin (Exubera) has advantages over short acting human insulin or insulin analogues administered subcutaneously. There are indications that inhaled insulin can cause severe hypoglycaemia more often than …

View Full Text

Log in

Log in through your institution


* For online subscription